People · Operator
Named in public records as an officer, director or promoter · active 2024–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Solve Therapeutics, Inc. | — | Biotechnology | Series C | $162.1M | $255.0M | 2024 |
Clayton D. Knox at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Clayton D. Knox on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Johnson | 1 | 35 |
| Alan Colowick | 1 | 7 |
| Peter Colabuono | 1 | 4 |
| Robert D. Mittendorff | 1 | 2 |
| Langdon Miller | 1 | 2 |
| Jason Pitts | 1 | 1 |
| Daniel D. McHugh | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.